系统性硬化症患者早期与延迟接受潜在改善病情治疗的结局比较
单中心回顾性队列研究纳入发病6年内接受环磷酰胺、吗替麦考酚酯、甲氨蝶呤或托珠单抗治疗的弥漫性皮肤型系统性硬化症或间质性肺病患者,按治疗开始时病程≤18个月与>18个月分为早期干预组(n=25)和延迟干预组(n=21)。早期干预组1年内肺功能稳定者比例低于延迟干预组(OR 0.087,95%CI 0.0079–0.51,P=0.003),但早期干预组活动性疾病比例从79%降至42%(P=0.007),且无修订版ACR-CRISS和PF-ILD定义的临床恶化事件累积率显著高于延迟干预组(P=0.03和0.003)。作者认为系统性硬化症患者中可能存在治疗「机会窗」。
要点
- 早期干预组1年内肺功能稳定比例低于延迟干预组(OR 0.087,95%CI 0.0079–0.51,P=0.003)。
- 早期干预组活动性疾病比例从79%降至42%(P=0.007),延迟干预组从68%降至42%(P=0.11),未达统计学显著。
- 无修订版ACR-CRISS和PF-ILD定义的临床恶化事件累积率早期干预组显著高于延迟干预组(P=0.03和0.003)。
核心结论
- 作者认为系统性硬化症患者中可能存在治疗「机会窗」。
研究设计与样本
- 单中心回顾性队列研究,纳入发病6年内因弥漫性皮肤型系统性硬化症或间质性肺病接受环磷酰胺、吗替麦考酚酯、甲氨蝶呤或托珠单抗治疗的系统性硬化症患者。
- 按治疗开始时病程≤18个月和>18个月分为早期干预组(n=25)和延迟干预组(n=21)。
- 临床恶化定义为发生任何原始或修订版ACR-CRISS第1步事件或进展性纤维化性间质性肺病(PF-ILD)。
主要发现
- 早期干预组与延迟干预组基线特征除用力肺活量外无差异,用力肺活量早期干预组优于延迟干预组。
- 早期干预组1年内肺功能稳定者比例低于延迟干预组(OR 0.087,95%CI 0.0079–0.51,P=0.003)。
- 早期干预组活动性疾病比例从79%降至42%(P=0.007),延迟干预组从68%降至42%(P=0.11),未达统计学显著。
- 无修订版ACR-CRISS和PF-ILD定义的临床恶化事件累积率早期干预组显著高于延迟干预组(P=0.03和0.003)。
关键数值与推荐
- 早期干预定义为治疗开始时病程≤18个月,延迟干预定义为治疗开始时病程>18个月。
- 临床恶化定义为发生任何原始或修订版ACR-CRISS第1步事件或PF-ILD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether early therapeutic intervention, compared with delayed intervention, is beneficial for patients with early SSc. METHODS: This is a single-centre, retrospective cohort study of SSc patients who received CYC, MMF, MTX or tocilizumab for diffuse cutaneous SSc (dcSSc) or interstitial lung disease (ILD) within 6 years after disease onset. The patients were divided into early and delayed intervention groups based on the disease duration of ≤18 and >18 months at treatment introduction, respectively. Clinical worsening was defined as the development of any original or revised ACR Composite Response Index in SSc (CRISS) step 1 event or progressive fibrosing ILD (PF-ILD). RESULTS: There was no difference in baseline characteristics between the early (n = 25) and delayed (n = 21) intervention groups except forced vital capacity, which was better in the early vs delayed intervention groups. The early intervention group less frequently had stable pulmonary function over 1 year than did the late intervention group (odds ratio 0.087, 95% CI: 0.0079, 0.51; P = 0.003). The active disease was significantly decreased from 79% to 42% in the early intervention group (P = 0.007), but the change in the delayed intervention group was not statistically significant (68% to 42%; P = 0.11). Cumulative rates free from clinical worsening events defined by revised ACR-CRISS and PF-ILD were significantly higher in the early vs delayed intervention groups (P = 0.03 and 0.003, respectively). CONCLUSION: A therapeutic 'window of opportunity' might exist in SSc patients.
引用
- Yomono K, Kuwana M. Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies. Rheumatology (Oxford). 2022. PMID: 34919668. doi:10.1093/rheumatology/keab931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。